Single-dose NEPA versus 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with risk factors receiving moderately emetogenic chemotherapy (MEC)

被引：1
|
作者：
Zelek, L. [1 ]
Debourdeau, P. [2 ]
Bourgeois, H. [3 ]
Wagner, J. P. [4 ]
Brocard, F. [5 ]
Lefeuvre-Plesse, C. [6 ]
Chauffert, B. [7 ]
Leheurteur, M. [8 ]
Bachet, J-B. [9 ]
Simon, H. [10 ]
Mayeur, D. [11 ]
Jovenin, N. [12 ]
Scotte, F. [13 ]
机构：
[1] Hop Avicenne, AP HP, Med Oncol, Bobigny, France
[2] Inst St Catherine, Oncol Support Care, Avignon, France
[3] Clin Victor Hugo, Med Oncol, Le Mans, France
[4] Inst Andree Dutreix & Clin Flandre, Res Innovat & External Commun, Dunkerque, France
[5] Polyclin Gentilly, Med Oncol, Nancy, France
[6] Ctr Eugene Marquis, Med Oncol, Rennes, France
[7] CHU Amiens Picardie Site Nord, Med Oncol Dept, Amiens, France
[8] Ctr Henri Becquerel, Med Oncol, Rouen, France
[9] Grp Hosp Pitie Salpetriere, Serv Hepatogastroenterol, Paris, France
[10] CHU Morvan, Inst Cancerol & Hematol, Brest, France
[11] Ctr George Francois Leclerc, Med Oncol, Dijon, France
[12] Inst Canc Courlancy Reims, Med Oncol, Reims, France
[13] Gustave Roussy, Interdisciplinary Canc Course Dept, Canc Ctr, Villejuif, France
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1644
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1672P
引用
收藏
页码：S1175 / S1175
页数：1
相关论文
共 50 条
  • [31] Safety of rolapitant, a novel NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC)
    Urban, Laszlo
    Poma, Allen
    Dardeno, Michelle Motta
    Martell, Robert E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of highly or moderately emetogenic chemotherapy (HEC, MEC).
    Rapoport, Bernardo Leon
    Schwartzberg, Lee Steven
    Chasen, Martin Robert
    Powers, Daniel
    Arora, Sujata
    Navari, Rudolph M.
    Schnadig, Ian D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (29)
  • [33] Efficacy of Single-Dose NEPA versus 3-Day Aprepitant Regimen for Prevention of CINV: A Phase 3 Lung Cancer Subset Analysis
    Lu, S.
    Zhang, L.
    Dechaphunkul, A.
    Lanzarotti, C.
    Jordan, K.
    Aapro, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1831 - S1832
  • [34] Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer
    Joseph S. Bubalo
    Jon D. Herrington
    Marc Takemoto
    Patricia Willman
    Michael S. Edwards
    Casey Williams
    Alan Fisher
    Alison Palumbo
    Eric Chen
    Charles Blanke
    Charles D. Lopez
    Supportive Care in Cancer, 2018, 26 : 1273 - 1279
  • [35] Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer
    Bubalo, Joseph S.
    Herrington, Jon D.
    Takemoto, Marc
    Willman, Patricia
    Edwards, Michael S.
    Williams, Casey
    Fisher, Alan
    Palumbo, Alison
    Chen, Eric
    Blanke, Charles
    Lopez, Charles D.
    SUPPORTIVE CARE IN CANCER, 2018, 26 (04) : 1273 - 1279
  • [36] Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy
    Longo, Flavia
    Mansueto, Giovanni
    Lapadula, Vittoria
    De Sanctis, Rita
    Quadrini, Silvia
    Grande, Roberta
    Gori, Bruno
    Altavilla, Amelia
    D'Antoni, I.
    Del Signore, Ester
    Stumbo, Luciano
    De Luca, Cristina
    Cimadon, Barbara
    Cortesi, Enrico
    Gamucci, Teresa
    Di Seri, Marisa
    SUPPORTIVE CARE IN CANCER, 2011, 19 (08) : 1159 - 1164
  • [37] Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy
    Flavia Longo
    Giovanni Mansueto
    Vittoria Lapadula
    Rita De Sanctis
    Silvia Quadrini
    Roberta Grande
    Bruno Gori
    Amelia Altavilla
    I. D’Antoni
    Ester Del Signore
    Luciano Stumbo
    Cristina De Luca
    Barbara Cimadon
    Enrico Cortesi
    Teresa Gamucci
    Marisa Di Seri
    Supportive Care in Cancer, 2011, 19 : 1159 - 1164
  • [38] APREPITANT IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING ASSOCIATED WITH MODERATELY OR HIGHLY EMETOGENIC CHEMOTHERAPIES IN PATIENTS WITH GASTROINTESTINAL CANCER
    Boice, J.
    Brown, C.
    Taylor, A.
    Hardwick, J.
    Carides, A.
    ANNALS OF ONCOLOGY, 2009, 20 : 69 - 69
  • [39] Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving moderately emetogenic chemotherapy (MEC)
    Schnadig, Ian D.
    Modiano, Manuel R.
    Poma, Allen
    Hedley, Mary Lynne
    Martell, Robert E.
    Schwartzberg, Lee Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] Phase III design for a trial of single-dose fosaprepitant (FA) in preventing chemotherapy-induced nausea and vomiting (CINV) associated with moderately einetogenic chemotherapy (MEC).
    Noga, Stephen Joseph
    Weinstein, Cindy
    Camacho, Elber S.
    Khanani, Saleem A.
    Beckford-Brathwalte, Elizabeth
    Vallelos, Waldlmir
    McGowan, Kelly
    Tamburrl, Grace
    Force, Joanne
    Taylor, Arlene
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345